Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update.

24.5 mos; HR = 0.86 [0.66–1.12], P = 0.258) but this did not reach statistical significance.[ 46 ] Although the incidence of Grade 3–4 adverse events were higher in the afatinib arm, the rate of adverse events related to treatment discontinuation was similar in both arms.

also in 111,027 other papers

There was a nonsignificant trend toward improvement in OS (HR = 0.63); however, OS results were immature, with only 25% of events collected.

also in 5,406 other papers